On June 15th and 16th, 2026, IQS Barcelona hosted the TumorOUT Workshop, bringing together leading academic, clinical, and industrial partners across Europe.
Coordinated by Dr. Cristina Fornaguera from the NanoTher – Nano Therapies Lab at IQS, TumorOUT is an ambitious collaborative research effort uniting prominent European institutions. The initiative is part of the European TRANSCAN-3 call for cancer immunotherapy research, operating under the overarching theme “Next generation cancer immunotherapy: targeting the tumor microenvironment”. To achieve its goals, the consortium is backed by the vital support of the Instituto de Salud Carlos III and the Scientific Foundation of the Spanish Association Against Cancer (FCAECC).
The TumorOUT project is dedicated to developing an innovative and personalized therapeutic mRNA vaccine for non-small cell lung cancer (NSCLC), a disease known for its high mortality rates and resistance to many treatments. Utilizing targeted polymeric nanoparticles, the therapy aims to deliver encapsulated antigenic mRNA and other immunomodulators to efficiently target different mechanisms within the tumor microenvironment.
Showcasing Scientific Achievements
The workshop began on June 15th with a welcome session led by Dr. Salvador Borrós, Director of IQS, and Dr. Cristina Fornaguera. The entire first day was dedicated to presenting the final results of the project. Researchers from the consortium—including Dr. Jan Dörrie from Universitätsklinikum Erlangen, Dr. Julien Faget from INSERM, Dr. Hanna Bednarz from Bielefeld University, and Dr. Núria de la Iglesia from IrsiCaixa—shared their findings. These presentations generated engaging and insightful discussions about the scientific achievements made so far, and highlighted the opportunities that lie ahead for nanomedicine and personalized cancer therapies.
Industry Collaboration and the Future of Oncology
La segona jornada de l’esdeveniment, el 16 de juny, va comptar amb les aportacions d’un grup de ponents convidats en The second day of the event, June 16th, featured talks from an outstanding group of invited speakers representing academia, the pharmaceutical industry, and cancer research organizations. Topics of discussion included manufacturing strategies for advanced therapies, the role of global progress in cancer research, and the future of next-generation immunotherapies.
Participants heard perspectives from experts such as:
- Dr. Xavier Julia, Head of Pharmaceutical Innovation at Reig Jofre, who spoke about “Manufacturing Strategies for Sterile Liquid and Lyophilized Drug Products in Advanced Therapies”.
- Dr. Silve Vicent, Associate Professor and Investigator at Center of Applied Medical Research CIMA, who presented on “From biology to therapy in mutant KRAS lung cancer”.
- Dr. Patricia Nieto, Director of Scientific Projects at AECC, that talked about “Driving Global Progress: The Role of FCAECC in International Cancer Research”.
- Dr. Giovanni Fucà, Medical Director, Early Global Development, Oncology R&D at AstraZeneca, with a presentation focused on “Meeting in the Middle: Academia, Industry, and the Next Generation of NSCLC Immunotherapy”.
- Prof. MD PhD Olivier Adotevi, Director of laboratory INSERM at Inserm, who discussed “Prospect of cancer vaccines in lung cancer”.
- Prof. Karine Breckpot from Vrije Universiteit Brussel, who shared insights on “mRNA vaccine design to fight pathogens and cancer”.
The workshop concluded with a dynamic roundtable discussion, moderated by Dr. Cristina Fornaguera. This final conversation explored the future of innovation and collaboration in oncology, while strongly emphasizing the need to “humanize” research. The participants concluded that alongside scientific excellence, it is crucial to strengthen the connection with society and utilize social media to clearly communicate the impact of cancer research to patients, their families, and the general public.
The event successfully closed the project with new collaborations and renewed motivation to continue advancing personalized cancer therapies.

